ZMC(SH:600216) Xin Lang Cai Jing·2026-02-25 06:08Group 1 - Zhejiang Pharmaceutical Co., Ltd. experienced a stock price increase of 5.02%, reaching 16.52 CNY per share, with a trading volume of 519 million CNY and a turnover rate of 3.37%, resulting in a total market capitalization of 15.886 billion CNY [1] - The company, established on May 16, 1997, and listed on October 21, 1999, operates in the fields of life nutrition products, pharmaceutical manufacturing, and pharmaceutical commerce. The revenue composition is as follows: pharmaceuticals 51.44%, life nutrition products 47.06%, others 0.85%, and additional 0.66% [1] Group 2 - Among the top ten circulating shareholders of Zhejiang Pharmaceutical, a fund under Yinhua Fund holds a significant position. The fund, Innovation Medicine (159992), increased its holdings by 223,700 shares in the third quarter, totaling 6.5421 million shares, which represents 0.68% of the circulating shares. The estimated floating profit today is approximately 5.1682 million CNY [2] - Innovation Medicine (159992) was established on March 20, 2020, with a current scale of 12.421 billion CNY. Year-to-date, it has incurred a loss of 0.59%, ranking 5077 out of 5570 in its category; over the past year, it achieved a return of 14.23%, ranking 3252 out of 4305; since inception, it has a loss of 17.27% [2] Group 3 - The fund managers of Innovation Medicine are Ma Jun and Wang Shuai. As of the latest update, Ma Jun has a cumulative tenure of 13 years and 178 days, managing assets totaling 50.663 billion CNY, with the best fund return during his tenure being 144.61% and the worst being -75.62% [3] - Wang Shuai has a cumulative tenure of 6 years and 245 days, managing assets of 33.98 billion CNY, with the best fund return during his tenure being 89.62% and the worst being -31.79% [3]